Nanfang Hospital, Southern Medical University: Leukemia trials

The registry lists 41 Leukemia studies with Nanfang Hospital, Southern Medical University as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 23Phase 3 19Phase 4 1No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• HVA vs IA/DA or VA in the Treatment of ND HR-AMLRecruitingNCT06810791Phase 3
• A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLRecruitingNCT06220487Phase 2
• Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood LeukemiaRecruitingNCT06155188Not applicable
• A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction FailureNot yet recruitingNCT05875649
• Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 MutationNot yet recruitingNCT04980859Phase 3
• The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib MaintenanceStatus unknownNCT05601895
• The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCTStatus unknownNCT05596981
• The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCTStatus unknownNCT05596968
• Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AMLCompletedNCT05456048
• G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT05449899Phase 2/3
• Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AMLStatus unknownNCT05404516Phase 2
• Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CMLStatus unknownNCT05376852Phase 2
• Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem CellsStatus unknownNCT04991532
• Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AMLCompletedNCT04788420
• Induced-T Cell Like NK Cells for B Cell MalignanciesStatus unknownNCT04747093Phase 1/2
• Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute LeukemiaStatus unknownNCT04674345Phase 2/3
• CD19-CAR-T2 Cells for CD19 Positive B Cell MalignanciesCompletedNCT04605666Phase 2
• Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAMLCompletedNCT04424147Phase 2
• Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AMLStatus unknownNCT03701217Phase 2/3
• The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AMLStatus unknownNCT03665480Phase 2/3
• HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCTStatus unknownNCT03662087Phase 2/3
• Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AMLStatus unknownNCT03642236Phase 2/3
• Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplantsStatus unknownNCT03624530Phase 2/3
• Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCTStatus unknownNCT03596892Phase 2/3
• Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALLStatus unknownNCT03564704Phase 2/3
• Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALLStatus unknownNCT03564470Phase 2/3
• Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALLStatus unknownNCT03553238Phase 2/3
• Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCTStatus unknownNCT03530085Phase 2/3
• Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic LeukemiaStatus unknownNCT03331211
• Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+CompletedNCT02936089Not applicable
• Vitro Study of Tigecycline to Treat Chronic Myeloid LeukemiaStatus unknownNCT02883036
• MRD-directed Therapy for Low-risk and Intermediate-risk AML.CompletedNCT02870777Phase 2/3
• Hematopoietic Stem Cell Microtransplantation for in AMLStatus unknownNCT02676856Not applicable
• IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCTCompletedNCT02671708Phase 2/3
• BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCTCompletedNCT02670252Phase 3
• Allo-HSCT With Alternative Donor in Treatment of Hematologic MalignancyCompletedNCT02487069Not applicable
• Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AMLCompletedNCT02474290Phase 2/3
• Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia PatientsStatus unknownNCT01889407
• TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaStatus unknownNCT01883219Phase 2
• HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALLStatus unknownNCT01873807Phase 4
• Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic LeukemiaCompletedNCT01457040Phase 2/3